NRx Pharmaceuticals, Inc. (NRXP) Stock

NRx Pharmaceuticals, Inc. (NRXP) is a Healthcare stock trading at $3.96 (as of 2026-06-18), with a market capitalization of $160.13M and a trailing P/E of -6.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Valuation — source: SEC EDGAR (first-party)
Price	$3.96
Market Cap	$160.13M
P/E Ratio	-6.5
EV / EBITDA	-9.0
Price / Book	-11.59
Price / Sales	69.84
DCF Value (model)	$-7.03
DCF Upside vs Price	-277.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$1.23M
Net Margin	-2336.5%
Return on Equity	177.6%
Current Ratio	0.29

Financial Health — source: SEC EDGAR
Altman Z-Score	-36.30 (distress)

Valuation vs Sector & Industry
Stock P/E	-6.5
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-131.2%
vs Industry	-138.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	B Group, Inc. ($6.39M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Jonathan C. Javitt
Employees	2
Country	US
IPO Date	2017-12-04

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.